Amyloid Accumulation – Causes, Symptoms and Treatment
Amyloid accumulation refers to the pathological buildup of misfolded proteins (amyloid) in tissues and organs, which can lead to serious organ dysfunction and disease.
Things worth knowing about "Amyloid Accumulation"
Amyloid accumulation refers to the pathological buildup of misfolded proteins (amyloid) in tissues and organs, which can lead to serious organ dysfunction and disease.
What is Amyloid Accumulation?
Amyloid accumulation is the process by which amyloid fibrils – insoluble, misfolded protein aggregates – deposit in various tissues and organs throughout the body. These deposits disrupt normal tissue architecture and significantly impair organ function. The group of diseases caused by amyloid deposition is collectively known as amyloidosis. Amyloid can accumulate locally in a single organ or systemically throughout the entire body.
Causes and Pathogenesis
Amyloid accumulation occurs when certain proteins lose their normal three-dimensional structure and aggregate into insoluble fibers. The most common causes include:
- Chronic inflammatory diseases (e.g., rheumatoid arthritis, Crohn disease) – leading to AA amyloidosis through deposition of serum amyloid A protein
- Plasma cell disorders (e.g., multiple myeloma) – causing AL amyloidosis due to abnormal immunoglobulin light chains
- Genetic mutations – causing hereditary amyloidosis, such as mutated transthyretin (ATTR amyloidosis)
- Aging processes – wild-type transthyretin amyloidosis (formerly called senile systemic amyloidosis)
- Neurodegeneration – in Alzheimer disease, beta-amyloid (Aß) accumulates in the brain, forming so-called senile plaques
Affected Organs and Symptoms
Symptoms vary depending on the organ affected. Amyloid accumulation can involve virtually any organ system:
Heart
- Heart failure and reduced cardiac function
- Cardiac arrhythmias
- Shortness of breath on exertion or at rest
Kidneys
- Nephrotic syndrome (massive protein loss in the urine)
- Progressive kidney failure
Nervous System
- Peripheral neuropathy (tingling, numbness, pain in hands and feet)
- Autonomic dysfunction (e.g., orthostatic hypotension, gastrointestinal motility issues)
- Cognitive impairment (in cerebral amyloid deposition, as seen in Alzheimer disease)
Liver and Spleen
- Enlargement of the liver (hepatomegaly) and spleen (splenomegaly)
- Impaired liver function
Other Possible Symptoms
- Unexplained weight loss
- Pronounced fatigue and exhaustion
- Macroglossia (enlarged tongue, characteristic of AL amyloidosis)
- Carpal tunnel syndrome (often an early sign of ATTR amyloidosis)
Diagnosis
Diagnosing amyloid accumulation typically requires several investigative steps:
- Tissue biopsy with Congo red staining: Amyloid deposits show characteristic apple-green birefringence under polarized light – this is considered the gold standard of diagnosis
- Blood and urine tests: Detection of free light chains, elevated serum amyloid A, or transthyretin mutations
- Echocardiography and MRI: Assessment of cardiac function and the extent of cardiac amyloidosis
- Bone scintigraphy (DPD/HMDP scan): A nuclear medicine technique particularly useful for ATTR amyloidosis
- Genetic testing: To identify hereditary amyloidosis mutations
Treatment
Treatment depends on the type of amyloidosis, the organs involved, and the severity of the disease. The primary goal is to halt the further production of amyloid precursors and to preserve organ function.
AL Amyloidosis
- High-dose chemotherapy, often followed by autologous stem cell transplantation
- Newer agents such as daratumumab (anti-CD38 antibody) have shown promising results
AA Amyloidosis
- Treatment of the underlying inflammatory condition (e.g., with biologics or colchicine)
ATTR Amyloidosis
- Tafamidis: Stabilizes the transthyretin protein and slows disease progression
- RNA interference therapies (e.g., patisiran, inotersen): Reduce the production of misfolded transthyretin
- Liver transplantation: An option in hereditary ATTR amyloidosis, as the liver is the primary source of the mutant protein
Alzheimer-Associated Amyloid Accumulation
- New anti-amyloid antibodies (e.g., lecanemab, donanemab) target the removal of beta-amyloid plaques from the brain and are currently in clinical use or under regulatory review
Supportive Measures
- Symptomatic management of heart failure, kidney disease, and neuropathy
- Regular follow-up to monitor organ function and disease progression
References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New England Journal of Medicine. 2003;349(6):583-596.
- Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. American Journal of Hematology. 2022;97(6):818-829.
- Hawkins PN et al. Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine. 2015;47(8):625-638.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryCalorie expenditure
Calorie deficit
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Amyloid Accumulation-en